Media

BONESUPPORT – CERAMENT® BONE VOID FILLER RECEIVES FDA CLEARANCE FOR SPINAL INTERBODY FUSION PROCEDURES

Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration

Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma

Oncopeptides – Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica

Tom Plitz commences role as Chief Executive Officer of Precirix

Vicore publishes the year-end report

Vicore to Present at Upcoming Investor Conferences

Oncopeptides publishes year-end report 2023